238 related articles for article (PubMed ID: 33061299)
21. Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.
Liu C; Kuang S; Huang T; Wu J; Zhang L; Gong X
CNS Neurosci Ther; 2024 Apr; 30(4):e14730. PubMed ID: 38644565
[TBL] [Abstract][Full Text] [Related]
22. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
[TBL] [Abstract][Full Text] [Related]
23. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Sun Y; Du F; Gao M; Ji Q; Li Z; Zhang Y; Guo Z; Wang J; Chen X; Wang J; Chi Y; Tang P
Thyroid; 2018 Nov; 28(11):1455-1461. PubMed ID: 30142994
[TBL] [Abstract][Full Text] [Related]
24. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study).
Sun Y; Zhou A; Zhang W; Jiang Z; Chen B; Zhao J; Li Z; Wang L; Bi X; Zhao H; Liu K
Hepatol Int; 2021 Jun; 15(3):621-629. PubMed ID: 33826043
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study.
Li L; Zhang H; Xie Y; Su N; Su S; Zhang X; Cen W
Comput Math Methods Med; 2022; 2022():1475871. PubMed ID: 35251294
[TBL] [Abstract][Full Text] [Related]
26. What is the best front-line approach in patients with desmoid fibromatosis? - A retrospective analysis from a reference center.
Sobczuk P; Agnieszczak IM; Grycuk W; Czarnecka AM; Świtaj T; Koseła-Paterczyk H; Morysiński T; Zdzienicki M; Rutkowski P
Eur J Surg Oncol; 2021 Oct; 47(10):2602-2608. PubMed ID: 33994241
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
[No Abstract] [Full Text] [Related]
28. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Kummar S; O'Sullivan Coyne G; Do KT; Turkbey B; Meltzer PS; Polley E; Choyke PL; Meehan R; Vilimas R; Horneffer Y; Juwara L; Lih A; Choudhary A; Mitchell SA; Helman LJ; Doroshow JH; Chen AP
J Clin Oncol; 2017 May; 35(14):1561-1569. PubMed ID: 28350521
[TBL] [Abstract][Full Text] [Related]
29. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review.
Lv Y; Zhang J; Liu F; Song M; Hou Y; Liang N
Medicine (Baltimore); 2019 May; 98(22):e15749. PubMed ID: 31145289
[TBL] [Abstract][Full Text] [Related]
31. Anlotinib is effective in the treatment of advanced pancreatic cancer: a case report.
Li S; Niu M; Deng W; Li N; Wei C; Luo S
Anticancer Drugs; 2022 Jan; 33(1):e558-e561. PubMed ID: 34387586
[TBL] [Abstract][Full Text] [Related]
32. Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis.
Palassini E; Frezza AM; Mariani L; Lalli L; Colombo C; Fiore M; Messina A; Casale A; Morosi C; Collini P; Stacchiotti S; Casali PG; Gronchi A
Cancer J; 2017; 23(2):86-91. PubMed ID: 28410293
[TBL] [Abstract][Full Text] [Related]
33. Desmoid fibromatosis: MRI features of response to systemic therapy.
Sheth PJ; Del Moral S; Wilky BA; Trent JC; Cohen J; Rosenberg AE; Temple HT; Subhawong TK
Skeletal Radiol; 2016 Oct; 45(10):1365-73. PubMed ID: 27502790
[TBL] [Abstract][Full Text] [Related]
34. Oral vinorelbine in young patients with desmoid-type fibromatosis.
Kornreich L; Orbach D; Nicolas N; Brisse HJ; Berlanga P; Defachelles AS; Mansuy L; Verite C; Saumet L; Karanian M; Corradini N
Tumori; 2023 Oct; 109(5):511-518. PubMed ID: 37114926
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated/dedifferentiated liposarcoma: a single-center retrospective study.
Li ZK; Liu J; Deng YT; Jiang Y
Anticancer Drugs; 2021 Feb; 32(2):210-214. PubMed ID: 33290314
[TBL] [Abstract][Full Text] [Related]
36. Pazopanib therapy for desmoid tumors in adolescent and young adult patients.
Agresta L; Kim H; Turpin BK; Nagarajan R; Plemmons A; Szabo S; Dasgupta R; Sorger JI; Pressey JG
Pediatr Blood Cancer; 2018 Jun; 65(6):e26968. PubMed ID: 29384266
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Metronomic Therapy as a Low-Cost, Sustainable, Standard-of-Care Option in Desmoid Fibromatosis: Real-World Data From a Tertiary Care Center in India.
Bajpai J; Munot P; Kota K; Gupta G; Gala K; Gulia A; Rekhi B; Khanna N; Shetty N; Bhargava P; Srinivas S; Ostwal V; Patil V; Noronha V; Kulkarni S; Laskar S; Prabhash K; Chinnaswamy G; Gupta S; Banavali S
JCO Glob Oncol; 2024 May; 10():e2300308. PubMed ID: 38723218
[TBL] [Abstract][Full Text] [Related]
38. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
[TBL] [Abstract][Full Text] [Related]
39. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor).
de Camargo VP; Keohan ML; D'Adamo DR; Antonescu CR; Brennan MF; Singer S; Ahn LS; Maki RG
Cancer; 2010 May; 116(9):2258-65. PubMed ID: 20187095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
